Literature DB >> 31498530

Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells.

Odunayo O Mugisho1,2, Laverne D Robilliard3, Louise F B Nicholson1, E Scott Graham3, Simon J O'Carroll1.   

Abstract

Neuroinflammatory disorders such as Alzheimer's and Parkinson's diseases are characterised by chronic inflammation and loss of vascular integrity. Bradykinin 1 receptor (B1R) activation has been implicated in many neuroinflammatory diseases, but the contribution of B1R to inflammation and vascular breakdown is yet to be determined. As a result, the present study evaluated the effect of B1R stimulation using Des-Arg-9-BK on the cytokine profile and junctional properties of human cerebral microvascular endothelial cells (hCMVECs). Results showed that stimulation of B1R receptors increased secretion of pro-inflammatory cytokines, interleukin-6 (IL-6), IL-8, intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1), but decreased the expression of vascular endothelial growth factor (VEGF), a cytokine and growth factor required for maintenance of the vasculature. B1R stimulation also resulted in the loss of occludin expression at tight junctions with no change in VE-cadherin expression. There was also a significant increase in permeability to Evans blue albumin, suggesting an increase of vascular permeability. Taken together, these results suggest that B1R activation that occurs in neuroinflammatory diseases may contribute to both the inflammation and loss of blood-brain barrier integrity that is characteristic of these diseases.
© 2019 International Federation for Cell Biology.

Entities:  

Keywords:  blood-brain barrier; bradykinin; endothelial cells; inflammation; neurodegenerative diseases; pro-inflammatory cytokines

Year:  2019        PMID: 31498530     DOI: 10.1002/cbin.11232

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  6 in total

1.  Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity.

Authors:  Enrique Alfaro; Elena Díaz-García; Sara García-Tovar; Ester Zamarrón; Alberto Mangas; Raúl Galera; Kapil Nanwani-Nanwani; Rebeca Pérez-de-Diego; Eduardo López-Collazo; Francisco García-Río; Carolina Cubillos-Zapata
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

2.  The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.

Authors:  Miklós Lipcsey; Barbro Persson; Oskar Eriksson; Anna M Blom; Karin Fromell; Michael Hultström; Markus Huber-Lang; Kristina N Ekdahl; Robert Frithiof; Bo Nilsson
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

3.  Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in China.

Authors:  Shuang Wang; Qiang Zhang; Peng Wang; Huahong Ye; Xiaoqing Jing; Zhongdan Zhang; Shisheng Zhu; Tingting Luo; Zhaobin Zheng
Journal:  Open Med (Wars)       Date:  2021-03-03

Review 4.  SARS-CoV-2 involvement in central nervous system tissue damage.

Authors:  Muhammad Ali Haidar; Zaynab Shakkour; Mohammad Amine Reslan; Nadine Al-Haj; Perla Chamoun; Karl Habashy; Hasan Kaafarani; Shima Shahjouei; Sarah H Farran; Abdullah Shaito; Esber S Saba; Bassam Badran; Mirna Sabra; Firas Kobeissy; Maya Bizri
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

Review 5.  Neuroinflammation and Its Impact on the Pathogenesis of COVID-19.

Authors:  Mohammed M Almutairi; Farzane Sivandzade; Thamer H Albekairi; Faleh Alqahtani; Luca Cucullo
Journal:  Front Med (Lausanne)       Date:  2021-11-24

Review 6.  How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.

Authors:  Bo Nilsson; Barbro Persson; Oskar Eriksson; Karin Fromell; Michael Hultström; Robert Frithiof; Miklos Lipcsey; Markus Huber-Lang; Kristina N Ekdahl
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.